Aytu BioPharma Statistics
Total Valuation
Aytu BioPharma has a market cap or net worth of $16.66 million. The enterprise value is $13.62 million.
| Market Cap | 16.66M |
| Enterprise Value | 13.62M |
Important Dates
The last earnings date was Wednesday, May 15, 2024, after market close.
| Earnings Date | May 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Aytu BioPharma has 5.97 million shares outstanding. The number of shares has increased by 48.48% in one year.
| Shares Outstanding | 5.97M |
| Shares Change (YoY) | +48.48% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 3.33% |
| Owned by Institutions (%) | 30.11% |
| Float | 3.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 5.78 |
| PS Ratio | 0.18 |
| Forward PS | 0.89 |
| PB Ratio | 0.54 |
| P/FCF Ratio | 1.90 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 1.55 |
Financial Position
The company has a current ratio of 0.85, with a Debt / Equity ratio of 0.54.
| Current Ratio | 0.85 |
| Quick Ratio | 0.59 |
| Debt / Equity | 0.54 |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.91 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -40.50% and return on invested capital (ROIC) is -4.00%.
| Return on Equity (ROE) | -40.50% |
| Return on Assets (ROA) | -10.30% |
| Return on Capital (ROIC) | -4.00% |
| Revenue Per Employee | $625,053 |
| Profits Per Employee | -$91,227 |
| Employee Count | 150 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 2.42 |
Taxes
In the past 12 months, Aytu BioPharma has paid $1.07 million in taxes.
| Income Tax | 1.07M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +54.14% in the last 52 weeks. The beta is -1.41, so Aytu BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | -1.41 |
| 52-Week Price Change | +54.14% |
| 50-Day Moving Average | 2.99 |
| 200-Day Moving Average | 2.88 |
| Relative Strength Index (RSI) | 41.51 |
| Average Volume (20 Days) | 19,117 |
Short Selling Information
The latest short interest is 411,699, so 6.89% of the outstanding shares have been sold short.
| Short Interest | 411,699 |
| Short Previous Month | 455,895 |
| Short % of Shares Out | 6.89% |
| Short % of Float | 10.51% |
| Short Ratio (days to cover) | 15.76 |
Income Statement
In the last 12 months, Aytu BioPharma had revenue of $93.76 million and -$13.68 million in losses. Loss per share was -$2.44.
| Revenue | 93.76M |
| Gross Profit | 61.24M |
| Operating Income | -1.90M |
| Pretax Income | -12.61M |
| Net Income | -13.68M |
| EBITDA | -4.17M |
| EBIT | -12.61M |
| Loss Per Share | -$2.44 |
Balance Sheet
The company has $19.76 million in cash and $16.72 million in debt, giving a net cash position of $3.04 million or $0.51 per share.
| Cash & Cash Equivalents | 19.76M |
| Total Debt | 16.72M |
| Net Cash | 3.04M |
| Net Cash Per Share | $0.51 |
| Equity (Book Value) | 30.78M |
| Book Value Per Share | 5.15 |
| Working Capital | -12.56M |
Cash Flow
| Operating Cash Flow | 8.77M |
| Capital Expenditures | n/a |
| Free Cash Flow | 8.77M |
| FCF Per Share | $1.58 |
Margins
Gross margin is 65.32%, with operating and profit margins of -2.03% and -14.60%.
| Gross Margin | 65.32% |
| Operating Margin | -2.03% |
| Pretax Margin | -13.45% |
| Profit Margin | -14.60% |
| EBITDA Margin | -4.44% |
| EBIT Margin | -13.45% |
| FCF Margin | 9.35% |
Dividends & Yields
Aytu BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -48.48% |
| Shareholder Yield | -48.48% |
| Earnings Yield | -82.12% |
| FCF Yield | 52.60% |
Analyst Forecast
The average price target for Aytu BioPharma is $5.00, which is 79.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.00 |
| Price Target Difference | 79.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 3.48% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 6, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 6, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Aytu BioPharma has an Altman Z-Score of -3.04 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.04 |
| Piotroski F-Score | 3 |